Sugi Predict

Sugi Predict / Compounds / SCHEMBL20577989

SCHEMBL20577989

SCHEMBL20577989

CC(C)(C)OC(=O)Nc1ccc(F)c(NC(=O)c2cccc(C(F)(F)F)n2)c1

nearest known ligand 0.50

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 4/20 0.50
▸ ACKR3 P25106 2/20 0.48
▸ IRAK4 Q9NWZ3 11/20 0.46
▸ P2RX7 Q99572 1/20 0.45
▸ GRM4 Q14833 1/20 0.45
▸ RXFP1 Q9HBX9 1/20 0.44
▸ FLT3 P36888 1/20 0.44
▸ IRAK1 P51617 1/20 0.43
▸ CRBN Q96SW2 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20577982 0.88 GRM4 (0.42) CBLBACKR3GRM4RXFP1
SCHEMBL28679540 0.84 TAS2R14 (0.46) IRAK4RXFP1FLT3
SCHEMBL21200138 0.80 CBLB (0.55) CBLBACKR3IRAK4P2RX7IRAK1
SCHEMBL20577956 0.79 RXFP1 (0.48) RXFP1
SCHEMBL20577943 0.79 RXFP1 (0.47) GRM4RXFP1
SCHEMBL20578021 0.79 LMNA (0.46) —
SCHEMBL29286674 0.78 RAB9A (0.49) RXFP1
SCHEMBL29448759 0.78 RAB9A (0.49) RXFP1
SCHEMBL20578183 0.78 ACLY (0.47) RXFP1
SCHEMBL29448788 0.78 RXFP1 (0.53) CBLBRXFP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3412670-B1 PYRIDINE DERIVATIVES INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, PHARMACEUTICAL COMPOSITION CONTAINING THEM AND USE THEREOF SAMJIN PHARM CO LTD (KR) 2022-03-09 — — EP disclosed
US-10844062-B2 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof INCHEON UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION (KR) 2020-11-24 — — US disclosed
US-20190300531-A1 Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof SAMJIN PHARMACEUTICAL CO., LTD. (KR) 2019-10-03 — — US disclosed
EP-3412670-A1 PYRIDINE DERIVATIVE INHIBITING RAF KINASE AND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Samjin Pharmaceutical Co., Ltd. (KR) 2018-12-12 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190300531-A1 Pyridine Derivative Inhibiting RAF Kinase and Vascular Endothelial Growth Factor Receptor, Method for Preparing Same, Pharmaceutical Composition Containing Same, and Use Thereof BRAF, KDR, RAF1 CBLB 1473/4885ACKR3 1670/4885IRAK4 559/4885
US-10844062-B2 Pyridine derivative inhibiting RAF kinase and vascular endothelial growth factor receptor, method for preparing same, pharmaceutical composition containing same, and use thereof BRAF, KDR, RAF1 CBLB 1473/4885ACKR3 1670/4885IRAK4 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.